Literature DB >> 21546572

Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis.

Alice Banh1, Jing Zhang, Hongbin Cao, Donna M Bouley, Shirley Kwok, Christina Kong, Amato J Giaccia, Albert C Koong, Quynh-Thu Le.   

Abstract

Galectin-1 (Gal-1), a carbohydrate-binding protein whose secretion is enhanced by hypoxia, promotes tumor aggressiveness by promoting angiogenesis and T-cell apoptosis. However, the importance of tumor versus host Gal-1 in tumor progression is undefined. Here we offer evidence that implicates tumor Gal-1 and its modulation of T-cell immunity in progression. Comparing Gal-1-deficient mice as hosts for Lewis lung carcinoma cells where Gal-1 levels were preserved or knocked down, we found that tumor Gal-1 was more critical than host Gal-1 in promoting tumor growth and spontaneous metastasis. Enhanced growth and metastasis associated with Gal-1 related to its immunomodulatory function, insofar as the benefits of Gal-1 expression to Lewis lung carcinoma growth were abolished in immunodeficient mice. In contrast, angiogenesis, as assessed by microvessel density count, was similar between tumors with divergent Gal-1 levels when examined at a comparable size. Our findings establish that tumor rather than host Gal-1 is responsible for mediating tumor progression through intratumoral immunomodulation, with broad implications in developing novel targeting strategies for Gal-1 in cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546572      PMCID: PMC3129397          DOI: 10.1158/0008-5472.CAN-10-4157

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Secretion of the galectin family of mammalian carbohydrate-binding proteins.

Authors:  R C Hughes
Journal:  Biochim Biophys Acta       Date:  1999-12-06

2.  Unexpected autoantibody production in membrane Ig-mu-deficient/lpr mice.

Authors:  D Melamed; E Miri; N Leider; D Nemazee
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

3.  A critical role for B cells in the development of memory CD4 cells.

Authors:  P J Linton; J Harbertson; L M Bradley
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

4.  Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms.

Authors:  G A Rabinovich; R E Ramhorst; N Rubinstein; A Corigliano; M C Daroqui; E B Kier-Joffé; L Fainboim
Journal:  Cell Death Differ       Date:  2002-06       Impact factor: 15.828

5.  Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway.

Authors:  Po-Lin Kuo; Jen-Yu Hung; Shau-Ku Huang; Shah-Hwa Chou; Da-En Cheng; Yuh-Jyh Jong; Chih-Hsing Hung; Chih-Jen Yang; Ying-Ming Tsai; Ya-Ling Hsu; Ming-Shyan Huang
Journal:  J Immunol       Date:  2010-12-29       Impact factor: 5.422

6.  Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3.

Authors:  J Kopitz; C von Reitzenstein; S André; H Kaltner; J Uhl; V Ehemann; M Cantz; H J Gabius
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

7.  Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation.

Authors:  N Tinari; I Kuwabara; M E Huflejt; P F Shen; S Iacobelli; F T Liu
Journal:  Int J Cancer       Date:  2001-01-15       Impact factor: 7.396

8.  Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration.

Authors:  I Camby; N Belot; S Rorive; F Lefranc; C A Maurage; H Lahm; H Kaltner; Y Hadari; M M Ruchoux; J Brotchi; Y Zick; I Salmon; H J Gabius; R Kiss
Journal:  Brain Pathol       Date:  2001-01       Impact factor: 6.508

9.  Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients.

Authors:  F A van den Brûle; D Waltregny; V Castronovo
Journal:  J Pathol       Date:  2001-01       Impact factor: 7.996

10.  Splenic T zone development is B cell dependent.

Authors:  V N Ngo; R J Cornall; J G Cyster
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  45 in total

Review 1.  Engineering galectin-glycan interactions for immunotherapy and immunomodulation.

Authors:  Shaheen A Farhadi; Gregory A Hudalla
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

2.  Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential.

Authors:  Erika M Yazawa; Jenna E Geddes-Sweeney; Filiberto Cedeno-Laurent; Kempland C Walley; Steven R Barthel; Matthew J Opperman; Jennifer Liang; Jennifer Y Lin; Tobias Schatton; Alvaro C Laga; Martin C Mihm; Abrar A Qureshi; Hans R Widlund; George F Murphy; Charles J Dimitroff
Journal:  J Invest Dermatol       Date:  2015-03-10       Impact factor: 8.551

3.  Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.

Authors:  Gregory J Baker; Peter Chockley; Daniel Zamler; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

4.  Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.

Authors:  Marilyne Labrie; Lorenna Oliveira Fernandes De Araujo; Laudine Communal; Anne-Marie Mes-Masson; Yves St-Pierre
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

5.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

6.  Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Authors:  Neus Martínez-Bosch; Maite G Fernández-Barrena; Mireia Moreno; Elena Ortiz-Zapater; Jessica Munné-Collado; Mar Iglesias; Sabine André; Hans-Joachim Gabius; Rosa F Hwang; Françoise Poirier; Carolina Navas; Carmen Guerra; Martin E Fernández-Zapico; Pilar Navarro
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

7.  A transcriptional and metabolic signature of primary aneuploidy is present in chromosomally unstable cancer cells and informs clinical prognosis.

Authors:  Jason M Sheltzer
Journal:  Cancer Res       Date:  2013-09-16       Impact factor: 12.701

8.  Self-assembled glycopeptide nanofibers as modulators of galectin-1 bioactivity.

Authors:  Antonietta Restuccia; Ye F Tian; Joel H Collier; Gregory A Hudalla
Journal:  Cell Mol Bioeng       Date:  2015-06-15       Impact factor: 2.321

9.  Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer.

Authors:  Jie Chen; Su-Jun Zhou; Yun Zhang; Guo-Qiang Zhang; Tian-Zhou Zha; Yi-Zhong Feng; Kai Zhang
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

10.  Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.

Authors:  Isidro Machado; José Antonio López Guerrero; Samuel Navarro; Empar Mayordomo; Katia Scotlandi; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2013-05-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.